Efforts by the pharmaceutical industry to expand access to low-and-middle-income countries need to be “vastly accelerated” ...

Merck's subcutaneous version of Keytruda succeeded in Phase 3 trials, showing non-inferior results to its IV counterpart. The ...

They've got $70 million, two guys named Ned, and plans to go after early-stage science where other venture capital firms ...

Incyte’s $750 million buyout of Escient Pharmaceuticals is in a rough patch as a mid-stage chronic hives candidate was ...

Synapticure, a startup building digital health tools for people with neurodegenerative conditions and their caregivers, has ...

Therapists can’t be around for their patients 24/7. One startup is betting AI can be the solution. When trained with clinical ...

Biogen and UCB on Tuesday shared an expanded dataset for their Phase 3 lupus program, which they said two months ago ...

Regenxbio reported improved muscle function in boys with Duchenne muscular dystrophy using their gene therapy RGX-202. The ...

Alnylam's nucresiran showed promising results in Phase 1 trial for rare cardiomyopathy, achieving up to 96% TTR reduction at ...

New hepatitis D treatment data from Vir Biotechnology and Bluejay Therapeutics shows promising results in reducing viral levels. Both companies plan further trials, with Vir targeting Phase 3 in 2025.

Rocket Pharmaceuticals reported Monday that benefits from its Danon disease gene therapy were seen up to around five years after treatment.

Neurogene reported a patient experienced systemic hyperinflammatory syndrome during their Rett syndrome gene therapy trial. CEO Rachel McMinn confirmed the female patient is in critical condition. The ...